New Leaf Venture Partners L.l.c. Lowers stake in SAGE Therapeutics Inc (SAGE)

SAGE Therapeutics Inc (SAGE) : New Leaf Venture Partners L.l.c. reduced its stake in SAGE Therapeutics Inc by 15.47% during the most recent quarter end. The investment management company now holds a total of 132,674 shares of SAGE Therapeutics Inc which is valued at $7,212,159 after selling 24,284 shares in SAGE Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.SAGE Therapeutics Inc makes up approximately 5.06% of New Leaf Venture Partners L.l.c.’s portfolio.

Other Hedge Funds, Including , Schwab Charles Investment Management Inc boosted its stake in SAGE in the latest quarter, The investment management firm added 35,346 additional shares and now holds a total of 106,387 shares of SAGE Therapeutics Inc which is valued at $5,783,197. SAGE Therapeutics Inc makes up approx 0.01% of Schwab Charles Investment Management Inc’s portfolio.Bessemer Group Inc boosted its stake in SAGE in the latest quarter, The investment management firm added 37 additional shares and now holds a total of 32,865 shares of SAGE Therapeutics Inc which is valued at $1,688,275. SAGE Therapeutics Inc makes up approx 0.01% of Bessemer Group Inc’s portfolio. Sectoral Asset Management Inc sold out all of its stake in SAGE during the most recent quarter. The investment firm sold 52,250 shares of SAGE which is valued $2,684,083.Tiaa Cref Investment Management boosted its stake in SAGE in the latest quarter, The investment management firm added 13,744 additional shares and now holds a total of 102,265 shares of SAGE Therapeutics Inc which is valued at $4,475,116. American Century Companies Inc added SAGE to its portfolio by purchasing 32,053 company shares during the most recent quarter which is valued at $1,320,904.

SAGE Therapeutics Inc closed down -0.54 points or -1.03% at $51.66 with 5,20,386 shares getting traded on Monday. Post opening the session at $52.47, the shares hit an intraday low of $51.15 and an intraday high of $53.165 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Many Wall Street Analysts have commented on SAGE Therapeutics Inc. Stifel Initiated SAGE Therapeutics Inc on Nov 14, 2016 to “Buy”, Price Target of the shares are set at $90.Leerink Partners Resumed SAGE Therapeutics Inc on Oct 4, 2016 to “Outperform”, Price Target of the shares are set at $68.Raymond James Initiated SAGE Therapeutics Inc on Sep 13, 2016 to “Outperform”, Price Target of the shares are set at $75.

SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

SAGE Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on SAGE Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.